189 related articles for article (PubMed ID: 36165534)
1. Preoperative MRI-Based Radiomics of Brain Metastasis to Assess T790M Resistance Mutation After EGFR-TKI Treatment in NSCLC.
Fan Y; He L; Yang H; Wang Y; Su J; Hou S; Luo Y; Jiang X
J Magn Reson Imaging; 2023 Jun; 57(6):1778-1787. PubMed ID: 36165534
[TBL] [Abstract][Full Text] [Related]
2. Brain-Tumor Interface-Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR-TKI and T790M Resistance Mutation in Non-Small Cell Lung Carcinoma Brain Metastasis.
Fan Y; Wang X; Yang C; Chen H; Wang H; Wang X; Hou S; Wang L; Luo Y; Sha X; Yang H; Yu T; Jiang X
J Magn Reson Imaging; 2023 Dec; 58(6):1838-1847. PubMed ID: 37144750
[TBL] [Abstract][Full Text] [Related]
3. Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC.
Fan Y; Wang X; Dong Y; Cui E; Wang H; Sun X; Su J; Luo Y; Yu T; Jiang X
Eur Radiol; 2023 Nov; 33(11):7902-7912. PubMed ID: 37142868
[TBL] [Abstract][Full Text] [Related]
4. Radiomics evaluates the EGFR mutation status from the brain metastasis: a multi-center study.
Cao R; Pang Z; Wang X; Du Z; Chen H; Liu J; Yue Z; Wang H; Luo Y; Jiang X
Phys Med Biol; 2022 Jun; 67(12):. PubMed ID: 35588722
[No Abstract] [Full Text] [Related]
5. Radiomics for prediction of response to EGFR-TKI based on metastasis/brain parenchyma (M/BP)-interface.
Fan Y; Zhao Z; Wang X; Ai H; Yang C; Luo Y; Jiang X
Radiol Med; 2022 Dec; 127(12):1342-1354. PubMed ID: 36284030
[TBL] [Abstract][Full Text] [Related]
6. Combined radiomics of primary tumour and bone metastasis improve the prediction of EGFR mutation status and response to EGFR-TKI therapy for NSCLC.
Cheng Y; Wang H; Yuan W; Wang H; Zhu Y; Chen H; Jiang W
Phys Med; 2023 Dec; 116():103177. PubMed ID: 38000098
[TBL] [Abstract][Full Text] [Related]
7. Development and externally validate MRI-based nomogram to assess EGFR and T790M mutations in patients with metastatic lung adenocarcinoma.
Fan Y; Dong Y; Wang H; Wang H; Sun X; Wang X; Zhao P; Luo Y; Jiang X
Eur Radiol; 2022 Oct; 32(10):6739-6751. PubMed ID: 35729427
[TBL] [Abstract][Full Text] [Related]
8. Predicting EGFR T790M Mutation in Brain Metastases Using Multisequence MRI-Based Radiomics Signature.
Li Y; Lv X; Wang B; Xu Z; Wang Y; Sun M; Hou D
Acad Radiol; 2023 Sep; 30(9):1887-1895. PubMed ID: 36586758
[TBL] [Abstract][Full Text] [Related]
9. CT-based nomogram for early identification of T790M resistance in metastatic non-small cell lung cancer before first-line epidermal growth factor receptor-tyrosine kinase inhibitors therapy.
Li Y; Lv X; Wang Y; Xu Z; Lv Y; Hou D
Eur Radiol Exp; 2023 Nov; 7(1):64. PubMed ID: 37914925
[TBL] [Abstract][Full Text] [Related]
10. Tumor-liver interface in MRI of liver metastasis enables prediction of EGFR mutation in patients with lung cancer: A proof-of-concept study.
Hou S; Wang H; Wang X; Chen H; Zhou B; Meng R; Sha X; Chang S; Wang H; Jiang W
Med Phys; 2024 Feb; 51(2):1083-1091. PubMed ID: 37408393
[TBL] [Abstract][Full Text] [Related]
11. Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC.
Lu J; Ji X; Liu X; Jiang Y; Li G; Fang P; Li W; Zuo A; Guo Z; Yang S; Ji Y; Lu D
Sci Rep; 2024 Jan; 14(1):446. PubMed ID: 38172228
[TBL] [Abstract][Full Text] [Related]
12. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
13. Radiomics for Detection of the EGFR Mutation in Liver Metastatic NSCLC.
Hou S; Fan Y; Wang X; Su J; Ren M; Wu Y; Zhou J; Qu M; Luo Y; Jiang W
Acad Radiol; 2023 Jun; 30(6):1039-1046. PubMed ID: 35907759
[TBL] [Abstract][Full Text] [Related]
14. Using Radiomics to Differentiate Brain Metastases From Lung Cancer Versus Breast Cancer, Including Predicting Epidermal Growth Factor Receptor and human Epidermal Growth Factor Receptor 2 Status.
Shi J; Chen H; Wang X; Cao R; Chen Y; Cheng Y; Pang Z; Huang C
J Comput Assist Tomogr; 2023 Nov-Dec 01; 47(6):924-933. PubMed ID: 37948368
[TBL] [Abstract][Full Text] [Related]
15. Editorial for "Preoperative MRI-Based Radiomics of Brain Metastasis to Assess T790M Resistance Mutation After EGFR-TKI Treatment in NSCLC".
Chaurasia A; Marya A
J Magn Reson Imaging; 2023 Jun; 57(6):1788-1789. PubMed ID: 36282539
[No Abstract] [Full Text] [Related]
16. MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis.
Qi H; Hou Y; Zheng Z; Zheng M; Sun X; Xing L
Clin Radiol; 2024 Jul; 79(7):515-525. PubMed ID: 38637187
[TBL] [Abstract][Full Text] [Related]
17. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
18. Radiomics of Spinal Metastases Originating From Primary Nonsmall Cell Lung Cancer or Breast Cancer and Ability to Predict Epidermal Growth Factor Receptor Mutation/Ki-67 Levels.
Niu S; Zhang H; Wang X; Jiang W
J Comput Assist Tomogr; 2023 Jul-Aug 01; 47(4):643-649. PubMed ID: 37380152
[TBL] [Abstract][Full Text] [Related]
19. Multiparametric MRI-Based Radiomics Approaches for Preoperative Prediction of EGFR Mutation Status in Spinal Bone Metastases in Patients with Lung Adenocarcinoma.
Jiang X; Ren M; Shuang X; Yang H; Shi D; Lai Q; Dong Y
J Magn Reson Imaging; 2021 Aug; 54(2):497-507. PubMed ID: 33638577
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor].
Cao ZY; Wu W; Hou LK; Zhang W; Gao CX; Wu CY; Zhang LP
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):910-914. PubMed ID: 30522170
[No Abstract] [Full Text] [Related]
[Next] [New Search]
